Document Detail

Impact of metabolic syndrome on coronary patency after thrombolytic therapy for acute myocardial infarction.
MedLine Citation:
PMID:  19696662     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The metabolic syndrome (MS) is highly prevalent in patients with acute myocardial infarction. It has been shown that MS is associated with poor in-hospital outcome and long-term survival in patients with acute myocardial infarction. We aimed to investigate the effect of MS on the infarct-related artery patency in patients treated with thrombolytic therapy for acute myocardial infarction. METHODS: We retrospectively analyzed 116 patients who were admitted to our clinics with acute ST elevation myocardial infarction and received thrombolytic therapy within 12 h of chest pain. MS was diagnosed according to National Cholesterol Education Program Adult Treatment Panel III criteria. The flow in the infarct-related artery was analyzed according to the thrombolysis in myocardial infarction (TIMI) flow grade and corrected TIMI frame count. RESULTS: MS was present in 55.2% of patients. The proportion of patients with MS who achieved TIMI grade 3 f low after thrombolysis was significantly lower than that of patients without MS (41.5 vs. 58.5%, P < 0.001). Moreover, corrected TIMI frame counts were significantly higher inpatients with MS (58.3+/-34.8 vs. 44.7+/-28.1, P =0.02). On multivariate logistic regression analysis MS was the only independent predictor of TIMI flow less than 3 (P =0.03,odds ratio = 3.545, 95% confidence interval: 1.064-11.808). CONCLUSION: We have shown for the first time that patients with MS have lower rates of TIMI grade 3 flow and higher corrected TIMI frame counts after thrombolytic therapy for acute myocardial infarction.
Ayse Saatci Yasar; Emine Bilen; Mehmet Bilge; Ugur Arslantas; Fatih Karakas
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Coronary artery disease     Volume:  20     ISSN:  1473-5830     ISO Abbreviation:  Coron. Artery Dis.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-25     Completed Date:  2009-10-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9011445     Medline TA:  Coron Artery Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  387-91     Citation Subset:  IM    
Department of Cardiology, Ataturk Education and Research Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Artery Disease / complications,  drug therapy*,  physiopathology
Coronary Circulation*
Fibrinolytic Agents / administration & dosage*
Logistic Models
Metabolic Syndrome X / complications*,  physiopathology
Middle Aged
Myocardial Infarction / complications,  drug therapy*,  physiopathology
Odds Ratio
Recombinant Proteins / administration & dosage
Retrospective Studies
Risk Assessment
Risk Factors
Streptokinase / administration & dosage
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage
Treatment Outcome
Vascular Patency*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.-/Streptokinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acquired factor VIII inhibitors: case reports of paclitaxel and penicillin - induced entities.
Next Document:  Perioperative management of ambulatory surgical patients with diabetes mellitus.